CRBU (Caribou Biosciences) Asset Turnover: 0.02 (As of Mar. 2026)


CRBU Caribou Biosciences Inc CRBU
65 GF Score
Price $1.76
GF Value $1.69
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Caribou Biosciences Asset Turnover?

Caribou Biosciences CRBU +0.57% 65 Asset Turnover is 0.02 as of Mar. 2026. GuruFocus rates CRBU with a GF Score™ of 65/100 and a GF Value™ of $1.69 (Fairly Valued). The stock has 5 warning signs investors should review.

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Caribou Biosciences's Revenue for the three months ended in Mar. 2026 was $2.40 Mil. Caribou Biosciences's Total Assets for the quarter that ended in Mar. 2026 was $162.18 Mil. Therefore, Caribou Biosciences's Asset Turnover for the quarter that ended in Mar. 2026 was 0.02.

Asset Turnover is linked to ROE % through Du Pont Formula. Caribou Biosciences's annualized ROE % for the quarter that ended in Mar. 2026 was -89.51%. It is also linked to ROA % through Du Pont Formula. Caribou Biosciences's annualized ROA % for the quarter that ended in Mar. 2026 was -61.87%.

Caribou Biosciences  (NAS:CRBU) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Caribou Biosciences's annulized ROE % for the quarter that ended in Mar. 2026 is

ROE %**(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=-100.34/112.0965
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-100.34 / 9.588)*(9.588 / 162.1825)*(162.1825/ 112.0965)
=Net Margin %*Asset Turnover*Equity Multiplier
=-1046.52 %*0.0591*1.4468
=ROA %*Equity Multiplier
=-61.87 %*1.4468
=-89.51 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Caribou Biosciences's annulized ROA % for the quarter that ended in Mar. 2026 is

ROA %(Q: Mar. 2026 )
=Net Income/Total Assets
=-100.34/162.1825
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-100.34 / 9.588)*(9.588 / 162.1825)
=Net Margin %*Asset Turnover
=-1046.52 %*0.0591
=-61.87 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.

Caribou Biosciences Asset Turnover Related Terms

Caribou Biosciences Asset Turnover Historical Data

* Premium members only.

The historical data trend for Caribou Biosciences's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Caribou Biosciences Asset Turnover Chart

Caribou Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Asset Turnover
Get a 7-Day Free Trial 0.04 0.03 0.09 0.03 0.05

Caribou Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.02 0.02

CRBU vs YDES, PRQR, CRBP: Asset Turnover Comparison

For the Biotechnology subindustry, Caribou Biosciences's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Caribou Biosciences Asset Turnover vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Caribou Biosciences's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Caribou Biosciences's Asset Turnover falls into.


CRBU
65GF Score
Caribou Biosciences Inc CRBU
Asset Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Caribou Biosciences Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Caribou Biosciences's Asset Turnover for the fiscal year that ended in Dec. 2025 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2025 )/( (Total Assets (A: Dec. 2024 )+Total Assets (A: Dec. 2025 ))/ count )
=11.159/( (313.313+175.367)/ 2 )
=11.159/244.34
=0.05

Caribou Biosciences's Asset Turnover for the quarter that ended in Mar. 2026 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=2.397/( (175.367+148.998)/ 2 )
=2.397/162.1825
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.

Frequently Asked Questions Learn more about Asset Turnover →
What does a Asset Turnover of 0.02 mean?
Caribou Biosciences (CRBU) has a Asset Turnover of 0.02 as of Mar. 2026. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Caribou Biosciences and its competitors.
Is Caribou Biosciences' Asset Turnover too high?
Caribou Biosciences' current Asset Turnover is 0.02. Overall, Caribou Biosciences has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Caribou Biosciences' Asset Turnover compare to YDES and PRQR?
Caribou Biosciences' Asset Turnover of 0.02 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Turnover for a Biotechnology company?
A good Asset Turnover depends on the Biotechnology industry context. However, Asset Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Turnover mean?
A high Asset Turnover can signal that a stock is expensive relative to its fundamentals. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Caribou Biosciences and its competitors. Caribou Biosciences's current Asset Turnover is 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caribou Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Caribou Biosciences (CRBU) is currently considered Fairly Valued. The stock's GF Value™ is $1.69, compared to a current price of $1.76 — trading 4.1% above its estimated fair value. The current Asset Turnover is 0.02. Caribou Biosciences' overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Turnover calculated?
Asset Turnover is calculated from a company's financial statements. For Caribou Biosciences (CRBU), the current Asset Turnover is 0.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Caribou Biosciences (CRBU) Overvalued in 2026?

Based on GuruFocus' analysis, Caribou Biosciences stock appears to be overvalued. The current stock price of $1.76 is trading 4.1% above its estimated GF Value™ of $1.69. GuruFocus considers Caribou Biosciences to be Fairly Valued.

Key valuation signals for CRBU:

  • Asset Turnover: 0.02
  • GF Value™: $1.69 vs. price of $1.76 (4.1% above fair value)
  • GF Score™: 65/100 with 5 warning signs

No single metric tells the full story. See the CRBU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Caribou Biosciences Business Description

Address 2929 7th Street, Suite 105, Berkeley, CA, USA, 94710
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
65GF Score

Get the complete analysis for CRBU

Asset Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.76
Price
$1.69
GF Value